Cisplatin

"Cisplatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.

Descriptor ID	D002945
MeSH Number(s)	D01.210.375 D01.625.125 D01.710.100
Concept/Terms	Cisplatin Cisplatin cis-Diamminedichloroplatinum(II) Platinum Diamminodichloride Diamminodichloride, Platinum cis-Platinum cis Platinum Dichlorodiammineplatinum cis-Diamminedichloroplatinum cis Diamminedichloroplatinum cis-Dichlorodiammineplatinum(II) NSC-119875 NSC-119875 Platino Platino Platinol Platinol Biocisplatinum Biocisplatinum Platidiam Platidiam

Below are MeSH descriptors whose meaning is more general than "Cisplatin".

Chemicals and Drugs [D]
Inorganic Chemicals [D01]
Chlorine Compounds [D01.210]
Cisplatin [D01.210.375]
Nitrogen Compounds [D01.625]
Cisplatin [D01.625.125]
Platinum Compounds [D01.710]
Cisplatin [D01.710.100]

Below are MeSH descriptors whose meaning is related to "Cisplatin".

Below are MeSH descriptors whose meaning is more specific than "Cisplatin".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Cisplatin" by people in this website by year, and whether "Cisplatin" was a major or minor topic of these publications.

Bar chart showing 79 publications over 25 distinct years, with a maximum of 8 publications in 2015

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2000	0	1	1
2002	1	1	2
2003	1	0	1
2004	1	2	3
2005	2	3	5
2006	1	0	1
2007	0	1	1
2008	0	1	1
2009	0	1	1
2010	2	2	4
2011	4	2	6
2012	2	1	3
2013	3	2	5
2014	3	0	3
2015	5	3	8
2016	0	4	4
2017	3	0	3
2018	3	1	4
2019	1	3	4
2020	0	4	4
2021	1	1	2
2022	3	3	6
2023	1	1	2
2024	1	1	2
2025	2	1	3

Below are the most recent publications written about "Cisplatin" by people in Profiles.

Singh A, Gupta I, Saha P, Hole A, Anthony F, Natu A, Smoot DT, Ashktorab H, Chilakapati MK, Gupta S. Raman spectroscopy for detecting gastric and liver cancer cells that entered a tolerant persistence state to survive cisplatin chemotherapy. Biochem Biophys Res Commun. 2025 11 19; 790:152891.

View in: PubMed
Singh A, Natu A, Anthony F, Muthu H, Khade B, Smoot DT, Ashktorab H, Gupta S. The synergistic action of HDAC inhibitor with cisplatin impedes survival and proliferation of drug-tolerant persister in gastric and liver cancer cells. Clin Epigenetics. 2025 Oct 08; 17(1):168.

View in: PubMed
Yoshizawa M, Miyawaki Y, Sato H, Kawasaki T, Furube T, Matsui K, Suzuki Y, Toriumi T, Kishimoto Y, Ebara G, Hirano Y, Okamoto K, Sakuramoto S. Esophageal Lymphoepithelioma-like Carcinoma With a Remarkable Response to DCF Chemotherapy: A Case Report. Anticancer Res. 2025 Oct; 45(10):4643-4652.

View in: PubMed
Du K, Zhang X, Qin Y, Ma H, Bing C, Deng S, Chen Y, Qin J, Chang S, Xiao S, Peng L, Xie X, Feng X, Fu X, Wei Y, Fan X, Ashktorab H, Smoot D, Jin Z, Peng Y. MAP3K13-232aa encoded by circMAP3K13 enhances cisplatin-induced pyroptosis by directly binding to IKKa in gastric adenocarcinoma. Cell Death Dis. 2025 Sep 01; 16(1):667.

View in: PubMed
Matsui K, Miyawaki Y, Kobayashi R, Yoshizawa M, Toriumi T, Ebara G, Sato H, Sakuramoto S. Clinical advantages of two vs. three courses of neoadjuvant chemotherapy using docetaxel?+?cisplatin?+?5-fluorouracil to improve preoperative nutritional status and mitigate decreasing skeletal muscle in resectable esophageal cancer. Int J Clin Oncol. 2025 Oct; 30(10):1992-2002.

View in: PubMed
Rivera-Serrano M, Flores-Col?n M, Valiyeva F, Mel?ndez LM, Vivas-Mej?a PE. Upregulation of MMP3 Promotes Cisplatin Resistance in Ovarian Cancer. Int J Mol Sci. 2025 Apr 24; 26(9).

View in: PubMed
Bharti R, Dey G, Khan D, Myers A, Huffman OG, Saygin C, Braley C, Richards E, Sangwan N, Willard B, Lathia JD, Fox PL, Lin F, Jha BK, Brown JM, Yu JS, Dwidar M, Joehlin-Price A, Vargas R, Michener CM, Longworth MS, Reizes O. Cell surface CD55 traffics to the nucleus leading to cisplatin resistance and stemness by inducing PRC2 and H3K27 trimethylation on chromatin in ovarian cancer. Mol Cancer. 2024 Jun 10; 23(1):121.

View in: PubMed
Corsi NJ, Stephens A, Finati M, Malchow T, Morrison C, Davis M, Hares K, Corsi MP, Arora S, Chiarelli G, Cirulli GO, Autorino R, Sood A, Rogers C, Abdollah F. Testing the external validity of the POUT III trial (adjuvant platnium-based chemotherapy in upper tract urothelial carcinoma) in a North American cohort. Urol Oncol. 2024 06; 42(6):175.e19-175.e25.

View in: PubMed
Anchoori RK, Anchoori V, Lam B, Tseng SH, Das S, Velasquez FC, Karanam B, Poddatoori D, Patnam R, Rudek MA, Chang YN, Roden RBS. Development and anticancer properties of Up284, a spirocyclic candidate ADRM1/RPN13 inhibitor. PLoS One. 2023; 18(6):e0285221.

View in: PubMed
Matilionyte G, Forsyth G, Guo J, Rimmer MP, Hermann BP, Anderson RA, Mitchell RT. Granulocyte-colony stimulating factor does not prevent in vitro cisplatin-induced germ cell reduction in immature human and mouse testis. BMC Cancer. 2023 Mar 16; 23(1):251.

View in: PubMed

People

Explore

Similar Concepts

Top Journals